Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQ-129 intravitreal sustained-release injection in macular edema secondary to BRVO/CRVO
CTR20254541Phase 2Active
- Sponsor
- Xingqi Eye Medicine
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SQ-129 in Vein occlusion (RVO), branch retinal vein occlusion (BRVO), central retinal vein occlusion with macular edema, sponsored by Xingqi Eye Medicine. Started Nov 2025; status: active.
02
Drugs
SQ-129
03
Conditions
Vein occlusion (RVO)branch retinal vein occlusion (BRVO)central retinal vein occlusion with macular edema
Beyond the preview
Go deeper on CTR20254541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254541.